Evidence map›Paper›PMID 37476563›Full record

ArticleCase reports in oncology

Langerhans Cell Histiocytosis with Good Response to Low-Dose Imatinib: Case Report and Literature Review.

Mohammed Abdulgayoom, Deena Mudawi, Zsolt Lengyel, Hayan Abo Samra, Awni Alshurafa, Mohamed A Yassin

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Case reports in oncology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Mohammed AbdulgayoomDepartment of Hematology, National Center for Cancer Care and Research, HMC, Doha, Qatar.
Deena MudawiDepartment of Hematology, National Center for Cancer Care and Research, HMC, Doha, Qatar.
Zsolt LengyelDepartment of PET/CT and Nuclear Medicine, HMC, Doha, Qatar.
Hayan Abo SamraDepartment of Laboratory Medicine and Pathology, HMC, Doha, Qatar.
Awni AlshurafaDepartment of Hematology, National Center for Cancer Care and Research, HMC, Doha, Qatar.
Mohamed A YassinDepartment of Hematology, National Center for Cancer Care and Research, HMC, Doha, Qatar.
National Center for Cancer Care and Research · QAQatar Airways (Qatar) · QA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Langerhans cell histiocytosis (LCH) is a rare neoplastic disease characterized by infiltration of histiocytes and dendritic cells into body organs. While treatment is better established in pediatrics, there is still no consensus on therapy in the adult population. Imatinib has shown promising results in some case reports and a small clinical trial. We present here a fifty-nine-year-old patient with LCH in the lung, liver, and bone who responded well to an imatinib dose of 100 mg daily. Her symptoms improved within 3 months of treatment, and subsequent positron emission tomography-computed tomography (PET/CT) showed resolution of 18F-fluorodeoxyglucose (FDG)-avid lesions.

Indexed as

Dendritic cell neoplasmsHistiocytic cell neoplasmsHistiocytosisPositron emission tomography scanTyrosine kinase inhibitors

Identifiers

PMID37476563
PMCPMC10355039
OpenAlexW4384925176

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.